免疫病毒疗法治疗脑胶质瘤和其他恶性脑肿瘤。
Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.
机构信息
Department of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA.
Department of Neurosurgery, The University of Alabama at Birmingham, 1060 Faculty Office Tower 510 20th Street South, Birmingham, AL, USA; Department of Pediatrics, Division of Pediatric Hematology-Oncology, The University of Alabama at Birmingham.
出版信息
Neurosurg Clin N Am. 2021 Apr;32(2):265-281. doi: 10.1016/j.nec.2020.12.008. Epub 2021 Feb 18.
Abstract
Glioblastoma multiforme (GBM) represents one of the most challenging malignancies due to many factors including invasiveness, heterogeneity, and an immunosuppressive microenvironment. Current treatment modalities have resulted in only modest effect on outcomes. The development of viral vectors for oncolytic immunovirotherapy and targeted drug delivery represents a promising therapeutic prospect for GBM and other brain tumors. A host of genetically engineered viruses, herpes simplex virus, poliovirus, measles, and others, have been described and are at various stages of clinical development. Herein we provide a review of the advances and current state of oncolytic virotherapy for the targeted treatment of GBM and malignant gliomas.
摘要
多形性胶质母细胞瘤（GBM）是最具挑战性的恶性肿瘤之一，原因包括侵袭性、异质性和免疫抑制性微环境。目前的治疗方法仅对结果产生了适度的影响。病毒载体用于溶瘤免疫病毒疗法和靶向药物输送的开发为 GBM 和其他脑肿瘤的治疗提供了有前途的治疗前景。一系列经过基因工程改造的病毒，如单纯疱疹病毒、脊髓灰质炎病毒、麻疹病毒等，已经被描述出来，并处于不同的临床开发阶段。本文综述了溶瘤病毒治疗 GBM 和恶性胶质瘤的靶向治疗的进展和现状。
相似文献
1
Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.免疫病毒疗法治疗脑胶质瘤和其他恶性脑肿瘤。
Neurosurg Clin N Am. 2021 Apr;32(2):265-281. doi: 10.1016/j.nec.2020.12.008. Epub 2021 Feb 18.
2
Implications of immune cells in oncolytic herpes simplex virotherapy for glioma.免疫细胞在单纯疱疹病毒溶瘤疗法治疗脑胶质瘤中的意义。
Brain Tumor Pathol. 2022 Apr;39(2):57-64. doi: 10.1007/s10014-022-00431-8. Epub 2022 Apr 6.
3
The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies.溶瘤单纯疱疹病毒作为治疗脑恶性肿瘤新型疗法的现状。
Viruses. 2021 Jun 17;13(6):1158. doi: 10.3390/v13061158.
4
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.溶瘤单纯疱疹病毒免疫病毒疗法联合免疫检查点阻断治疗胶质母细胞瘤。
Immunotherapy. 2018 Jul;10(9):779-786. doi: 10.2217/imt-2018-0009.
5
Oncolytic viruses as a promising therapeutic strategy against the detrimental health impacts of air pollution: The case of glioblastoma multiforme.溶瘤病毒作为一种有前途的治疗策略，对抗空气污染对健康的不利影响：以多形性胶质母细胞瘤为例。
Semin Cancer Biol. 2022 Nov;86(Pt 3):1122-1142. doi: 10.1016/j.semcancer.2021.05.013. Epub 2021 May 15.
6
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.人胶质母细胞瘤来源的癌症干细胞：侵袭性胶质瘤模型的建立及溶瘤性单纯疱疹病毒载体治疗
Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886. Epub 2009 Apr 7.
7
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.恶性脑胶质瘤溶瘤病毒治疗的临床现状、挑战与未来方向的更新。
Curr Treat Options Oncol. 2024 Jul;25(7):952-991. doi: 10.1007/s11864-024-01211-6. Epub 2024 Jun 19.
8
Clinical advances in oncolytic virotherapy for pediatric brain tumors.小儿脑肿瘤溶瘤病毒治疗的临床进展。
Pharmacol Ther. 2022 Nov;239:108193. doi: 10.1016/j.pharmthera.2022.108193. Epub 2022 Apr 26.
9
Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.麻疹病毒株联合抗程序性死亡蛋白1（PD-1）抗体阻断的免疫病毒疗法可增强胶质母细胞瘤治疗中的抗肿瘤活性。
Neuro Oncol. 2017 Apr 1;19(4):493-502. doi: 10.1093/neuonc/now179.
10
Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.溶瘤单纯疱疹病毒治疗脑胶质瘤和靶向脑胶质瘤干细胞。
Front Cell Infect Microbiol. 2023 May 31;13:1206111. doi: 10.3389/fcimb.2023.1206111. eCollection 2023.
引用本文的文献
1
Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.溶瘤单纯疱疹病毒疗法：最新进展、核心挑战与未来展望。
Vaccines (Basel). 2025 Aug 20;13(8):880. doi: 10.3390/vaccines13080880.
2
Cell and gene therapy in neuro-oncology.神经肿瘤学中的细胞和基因治疗。
Handb Clin Neurol. 2024;205:297-315. doi: 10.1016/B978-0-323-90120-8.00009-5.
3
An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas.恶性脑胶质瘤溶瘤病毒治疗的临床现状、挑战与未来方向的更新。
Curr Treat Options Oncol. 2024 Jul;25(7):952-991. doi: 10.1007/s11864-024-01211-6. Epub 2024 Jun 19.
4
OV Modulators of the Paediatric Brain TIME: Current Status, Combination Strategies, Limitations and Future Directions.儿科大脑中的 OV 调节剂：当前状态、联合策略、局限性和未来方向。
Int J Mol Sci. 2024 May 3;25(9):5007. doi: 10.3390/ijms25095007.
5
Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults.免疫疗法在成人复发性胶质母细胞瘤中的临床应用
Cancers (Basel). 2023 Jul 31;15(15):3901. doi: 10.3390/cancers15153901.
6
Characterization and Optimization of the Tumor Microenvironment in Patient-Derived Organotypic Slices and Organoid Models of Glioblastoma.胶质母细胞瘤患者来源的器官型切片和类器官模型中肿瘤微环境的表征与优化
Cancers (Basel). 2023 May 10;15(10):2698. doi: 10.3390/cancers15102698.
7
Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies.胶质母细胞瘤免疫抑制微环境中的髓系细胞：特征和治疗策略。
Front Immunol. 2023 Feb 27;14:994698. doi: 10.3389/fimmu.2023.994698. eCollection 2023.
8
Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions.儿科脑与脊柱肿瘤的免疫治疗：现状与未来方向。
Pediatr Neurosurg. 2023;58(5):313-336. doi: 10.1159/000528792. Epub 2022 Dec 22.
9
Gene Therapy for High Grade Glioma: The Clinical Experience.基因治疗高级别神经胶质瘤：临床经验。
Expert Opin Biol Ther. 2023 Feb;23(2):145-161. doi: 10.1080/14712598.2022.2157718. Epub 2022 Dec 16.
10
Tumour microenvironment: Modulating effects, challenges, and future perspectives of oncolytic virotherapy in Astrocytoma treatment.肿瘤微环境：溶瘤病毒疗法在星形细胞瘤治疗中的调节作用、挑战及未来展望
Ann Med Surg (Lond). 2022 Aug 28;82:104508. doi: 10.1016/j.amsu.2022.104508. eCollection 2022 Oct.
本文引用的文献
1
Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells.一种由Ki67核心启动子驱动并携带IL-15的新型双控溶瘤腺病毒对胶质母细胞瘤细胞的疗效。
Cell Biosci. 2020 Oct 27;10:124. doi: 10.1186/s13578-020-00485-1. eCollection 2020.
2
Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture.鉴定胶质母细胞瘤和结直肠癌中 CAR T 细胞的靶向治疗靶点：一项艰巨的任务。
Front Immunol. 2020 Sep 30;11:565631. doi: 10.3389/fimmu.2020.565631. eCollection 2020.
3
Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.溶瘤单纯疱疹病毒 G207 治疗小儿脑恶性小脑脑肿瘤的首次人体 1 期免疫病毒治疗临床试验的设计与原理。
Hum Gene Ther. 2020 Oct;31(19-20):1132-1139. doi: 10.1089/hum.2020.101. Epub 2020 Aug 17.
4
Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.低剂量溶瘤腺病毒疗法可克服肿瘤诱导的免疫抑制，并使颅内胶质瘤对抗PD-1疗法敏感。
Neurooncol Adv. 2020 Feb 3;2(1):vdaa011. doi: 10.1093/noajnl/vdaa011. eCollection 2020 Jan-Dec.
5
Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.新城疫病毒（NDV）在人胶质瘤肿瘤中的溶瘤活性依赖于 CDKN2A 型 I 型干扰素基因簇缺失。
Cells. 2020 Jun 5;9(6):1405. doi: 10.3390/cells9061405.
6
The Frequency of Ras Mutations in Cancer.癌症中 Ras 突变的频率。
Cancer Res. 2020 Jul 15;80(14):2969-2974. doi: 10.1158/0008-5472.CAN-19-3682. Epub 2020 Mar 24.
7
Study protocol of a Phase I/IIa clinical trial of Ad-SGE-REIC for treatment of recurrent malignant glioma.一项关于 Ad-SGE-REIC 治疗复发性恶性脑胶质瘤的 I/IIa 期临床试验方案。
Future Oncol. 2020 Feb;16(6):151-159. doi: 10.2217/fon-2019-0743. Epub 2020 Jan 24.
8
A novel in situ multiplex immunofluorescence panel for the assessment of tumor immunopathology and response to virotherapy in pediatric glioblastoma reveals a role for checkpoint protein inhibition.一种用于评估儿童胶质母细胞瘤肿瘤免疫病理学和病毒疗法反应的新型原位多重免疫荧光检测方法揭示了检查点蛋白抑制的作用。
Oncoimmunology. 2019 Oct 21;8(12):e1678921. doi: 10.1080/2162402X.2019.1678921. eCollection 2019.
9
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.美国 2012-2016 年诊断的原发性脑和其他中枢神经系统肿瘤 CBTRUS 统计报告。
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.
10
Molecular and cellular intratumoral heterogeneity in primary glioblastoma: clinical and translational implications.原发性胶质母细胞瘤的分子和细胞内肿瘤异质性：临床及转化意义
J Neurosurg. 2019 Aug 23;133(3):655-663. doi: 10.3171/2019.5.JNS19364. Print 2020 Sep 1.
Zotero 插件